ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

MRK Merck and Co Inc

125.40
0.17 (0.14%)
19 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Merck and Co Inc MRK NYSE Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.17 0.14% 125.40 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
125.71 124.89 126.12 125.78 125.23
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
19/4/202406:04PRNCASanté Canada approuve KEYTRUDA® comme traitement de première..
10/4/202406:13IHMARKETNEWSDelta Generates US$37 Million Profit in Q1, Google and Intel..
04/4/202405:45BWMerck Initiates Phase 3 Clinical Trial of MK-1084, an..
03/4/202407:00BWREJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan..
01/4/202405:45BWMerck to Hold First-Quarter 2024 Sales and Earnings..
28/3/202405:45BWEuropean Commission Approves Merck’s KEYTRUDA®..
27/3/202405:54IHMARKETNEWSGameStop Shares Tumble 20% in Pre-Market Trading Amid..
26/3/202417:21BWFDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a..
21/3/202405:45BWMerck Provides Update on Phase 3 KEYLYNK-006 Trial..
19/3/202408:00BWMerck Announces Positive Data on V116, an Investigational,..
15/3/202415:23PRNUSFarmSee Ltd Announces the Completion of a Minority..
15/3/202405:45BWMerck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy..
13/3/202402:00BWMerck Announces Plans to Conduct Clinical Trials of a Novel..
11/3/202407:15BWMerck Completes Acquisition of Harpoon Therapeutics, Inc.
06/3/202409:25BWGilead and Merck Announce Phase 2 Data Showing an..
05/3/202408:03IHMARKETNEWSFutures Pointing To Continued Weakness On Wall Street
05/3/202405:45BWMerck to Participate in the Barclays 26th Annual Global..
04/3/202405:45BWMerck to Participate in the Leerink Partners Global..
27/2/202405:45BWMerck to Participate in the TD Cowen 44th Annual Health Care..
23/2/202405:20BWMerck Receives Positive EU CHMP Opinion for KEYTRUDA®..
20/2/202415:14EDGAR2Form 8-K - Current report
20/2/202405:45BWFDA Grants Priority Review to Merck's Application for..
15/2/202415:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202415:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202415:40EDGAR2Form 144 - Report of proposed sale of securities
14/2/202415:30EDGAR2Form 144 - Report of proposed sale of securities
14/2/202415:24EDGAR2Form 144 - Report of proposed sale of securities
13/2/202415:50EDGAR2Form 144 - Report of proposed sale of securities
13/2/202415:48EDGAR2Form 144 - Report of proposed sale of securities
12/2/202415:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202406:05PRNCASanté Canada approuve KEYTRUDA®, en association avec le..
09/2/202415:06EDGAR2Form 144 - Report of proposed sale of securities
08/2/202415:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/2/202406:00PRNCAMERCK CANADA ANNONCE UNE COLLABORATION AVEC L'INSTITUT..
07/2/202415:09EDGAR2Form 144 - Report of proposed sale of securities
05/2/202415:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202405:33BWMerck Animal Health to Acquire Elanco’s Aqua Business
02/2/202415:35EDGAR2Form 144 - Report of proposed sale of securities
02/2/202415:09EDGAR2Form 144 - Report of proposed sale of securities
02/2/202415:08EDGAR2Form 144 - Report of proposed sale of securities
02/2/202415:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202415:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202405:39EDGAR2Form 8-K - Current report
01/2/202405:30BWMerck Announces Fourth-Quarter and Full-Year 2023 Financial..
27/1/202409:00BWMerck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death..
26/1/202410:49EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
26/1/202409:00BWMerck’s KEYTRUDA® (pembrolizumab) Significantly Improved..
25/1/202407:07DJNLava Therapeutics Shares Rise as Drug Set for Test With..
24/1/202415:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202415:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Su Consulta Reciente

Delayed Upgrade Clock